Weight Loss Drugs May Lower Risk of Dementia, Stroke: Study
TAIWAN, JUL 15 – A seven-year study of 60,000 people found GLP agonist drugs reduced dementia risk by 37% and stroke risk by 19% in individuals with type 2 diabetes and obesity.
- A new study suggests that medications like Ozempic and Mounjaro may help protect against dementia and stroke.
- During a seven-year follow-up, users of GLP agonist drugs had a 37% lower risk of dementia and a 19% reduced risk of stroke.
- Researchers noted potential neuroprotective benefits of semaglutide and tirzepatide.
- Type 2 diabetes patients taking semaglutide showed a significantly lower risk of dementia than those on other diabetic medications.
Insights by Ground AI
Does this summary seem wrong?
35 Articles
35 Articles
6
19
2
Other benefits weight loss drugs may be able to offer
For Tuesday, July 15, WGN’s Dina Bair has the latest on new medical information, including: Other benefits of weight loss drugs GLP-1 agonists may boost brain power and precent deadly neurological conditions. The Journal of the American Medical Association reports using medications like semaglutide and tirzepatide, sold as Wegovy, Ozempic, Mounjaro and Zepbound, is associated with a lower risk for dementia, stroke and mortality in adults with ty…
·Chicago, United States
Read Full ArticleWeight loss jabs 'may protect against dementia and stroke ...
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources35
Leaning Left6Leaning Right2Center19Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 22%
C 70%
Factuality
To view factuality data please Upgrade to Premium